tbuckley/cabot-search huggingface dataset:
CSIG-20. IDENTIFICATION OF A NAMPT-E2F2-ID1 SIGNALING AXIS IN GLIOBLASTOMA
Authors: Amit Gujar, Alice Turski, Son Le, Diane Mao, David Dadey, Diane Aum, Jingqin Luo, Dennis Hallahan, David Tran, Hiroko Yano, Albert Kim
Journal: Neuro-Oncology (2016)

Emerging evidence shows that nicotinamide adenine dinucleotide (NAD+)-dependent signaling plays a critical role in a variety of biological contexts including cancer. The rate-limiting enzyme of the mammalian NAD+ synthesis pathway, nicotinamide phosphoribosyltransferase (NAMPT), governs NAD+-dependent processes by catalyzing production of nicotinamide mononucleotide (NMN), a key NAD+ precursor. However, the role and molecular mechanisms of NAMPT in the biology of human glioblastoma have remained poorly understood. Here, we demonstrate that NAMPT is highly expressed in glioblastoma tumor specimens and patient-derived glioblastoma stem-like cells (GSCs). High NAMPT expression in glioblastoma tumors correlates with poor prognosis in patients. NAMPT inhibition using FK866 as well as RNA interference (RNAi) depleted NAD+ levels in GSCs and substantially decreased GSC self-renewal. Importantly, NAMPT knockdown diminished the in vivo tumorigenicity of GSCs and prolonged the survival of animals in an orthotopic xenograft model. Bioinformatic analysis of RNA-sequencing data derived from FK866-treated GSCs revealed E2F family transcription factor E2F2 as a potential hub of the NAD+-dependent transcriptome. Accordingly, E2F2 knockdown decreased the self-renewal capacity of GSCs. Downstream, we find that E2F2 directly controls the transcription of helix-loop-helix protein inhibitor of differentiation 1 (ID1), a known regulator of self-renewal. Finally, we show that NAMPT promotes radiation resistance of GSCs in culture, highlighting the potential therapeutic relevance of this pathway. The identification of a NAMPT-E2F2-ID1 signaling pathway, which regulates GSC maintenance, has ramifications for the development of novel therapeutic strategies for glioblastoma patients.
Antiendothelial Cell ABS (AECA) in Vasculitis induce Endothelial Adhesion Molecule (AM) Expression and Cytokine Secretion
Authors: A Radice, P Meroni, N Delpapa, J Shoenfeld, A Tincani, G Balestrieri, R Sinico, G Damico
Journal: Journal of the American Society of Nephrology (1995)
More than a third with COPD also have asthma symptoms, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

More than a third of adults with newly diagnosed chronic obstructive pulmonary disease (COPD) also have asthma symptoms, a general practice study has found.1

The past few years have seen growing recognition that a significant proportion of patients with COPD have features of asthma. But it is not clear how many people have this type of asthma-COPD overlap syndrome, and there is no generally agreed definition.

A …
Association of Unsolicited Patient Observations With the Quality of a Surgeon’s Care
Authors: Allen Kachalia, Michelle M. Mello, David M. Studdert
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Comparable Survival and Transplant-Related Mortality Following Allogeneic Hematopoietic Cell Transplantation from HLA Allele-Matched Unrelated and HLA-Identical Sibling Donors.
Authors: Thai M. Cao, Schickwann Tsai, Linda Kelley, Stephen C. Alder, Thomas C. Fuller, Michael A. Pulsipher
Journal: Blood (2006)
Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries
Authors: D.P. Miller, M. Roberts, V.I. Petkov, S. Shak, N. Howlader, K. Cronin, L. Penberthy
Journal: Annals of Oncology (2016)
Impact of Kras mutant subtypes on PD-L1 expression in lung adenocarcinoma
Authors: A.T. Falk, N. Yazbeck, L. Thon, N. Guibert, V. Hofman, K. Zahaf, V. Lespinet, O. Bordone, V. Tanga, K. Washetine, C. Cohen, N. Venissac, J. Mouroux, C.-H. Marquette, P. Brest, M. Ilié, P. Hofman
Journal: Annals of Oncology (2016)
P08.32 TG02, an oral CDK inhibitor, demonstrates activity in glioma models: EORTC Brain Tumor Group Conducts Phase 1b study (STEAM / EORTC 1608)
Authors: T. Parrott, M. Weller, T. M. Estok, E. Le Rhun
Journal: Neuro-Oncology (2016)

A distinct perivascular niche has been implicated in many aspects of tumor biology, particularly stemness, invasion, survival, and therapy resistance of cancer cells.But its overall importance for these factors remains obscure.By using multidimensional intravital imaging, that allows following individual glioblastoma cells in distinct brain microregions over long periods of time, we demonstrate that the perivascular niche plays a crucial role for many aspects of brain tumor progression.Glioblastoma stem-like cells (GBMSCs) colonized the perivascular niche in significant numbers, and used it as a route for effective brain invasion.This was partly explained by the fact that tumor microtubes (TMs), a novel cellular mechanism of glioblastoma progression and resistance (Osswald et al., Nature 2015), followed the perivascular room of the dense brain microcapillary network as a leading track.A subfraction of GBMSCs in a perivascular position showed long-term dormancy.Furthermore, location in the perivascular niche was associated with a high resistance against cytotoxic effects of radiotherapy, and with the ability of GBM-SCs to repair damage inflicted to their tumor microregion.Proficient NOTCH1 expression was required for successful perivascular niche colonization, and NOTCH1 deficiency reduced the radioresistance of perivascular tumor cells.Double-positivity for perivascular niche position and TM-formation was associated with the strongest primary resistance to therapies, and the strongest damage repair competence of an individual tumor cell.Taken together, these results provide the first direct evidence that a perivascular niche position is relevant for glioblastoma cells to exert central malignant traits, including those that have been associated with cancer stem-like cells.Targeting the subpopulation of glioma cells that colonizes the perivascular niche emerges as an important task for the development of novel therapies, since existing treatment modalities fall short of controlling these cells. P08.32 TG02,
Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients.
Authors: Hiroki Yokoyama, Takahiro Fukuda, Yukio Kobayashi, Sung-Won Kim, Dai Maruyama, Shin-ichiro Mori, Takashi Watanabe, Ryuji Tanosaki, Kinuko Tajima, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2007)
Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging
Authors: S. Cavalieri, A. Raimondi, D. Morelli, A. Martinetti, F. de Braud, F. Agustoni, K. Dotti, G. Galli, C. Vernieri, G. Fucà, G. Peverelli, M. Prisciandaro, F. Nichetti, P. Indelicato, G. Lo Russo, N. Prinzi, M. Garassino, M. Platania
Journal: Annals of Oncology (2016)
GENT-38. SINGLE MITOCHONDRIAL DNA VARIATIONS INFLUENCE MITOCHONDRIAL TARGETED DRUG SENSITIVITY IN IN VITRO MODELS OF GLIOBLASTOMA
Authors: Kathleen Keatley, Stephanie Lurshay, Stavros Polyzoidis, Keyoumars Ashkan, Helen Fillmore, Geoffrey Pilkington, Iain Hargreaves, Brigitte Meunier, John McGeehan, Rhiannon Lloyd
Journal: Neuro-Oncology (2016)

Glioblastoma is the most malignant and common primary brain tumour in adults, with a dismal prognosis. This is partly due to intra- and inter-tumoural heterogeneity, which contributes to differential cellular response to current therapies. This poor treatment efficacy continues to prompt researchers to look further into the molecular characteristics of glioblastoma, as well as alternative chemotherapeutic targets, such as the mitochondria. We have previously characterised the mitochondrial DNA (mtDNA) variation landscape of glioblastoma. Using two in vitro models, we have also investigated the effect of mtDNA variations on clomipramine sensitivity. Clomipramine is known to inhibit mitochondrial respiratory chain complex III (CIII), as well as glioblastoma cell growth. As human mtDNA is recalcitrant to genetic manipulation, a single glioblastoma-associated variation was introduced into yeast cytochrome b. The variation, which occurs within the CIII inhibitor binding Qi-site, and is equivalent to m.14798T>C (p.Phe18Leu) found in ~31% of glioblastoma samples tested to date, increased the CIII sensitivity of yeast cells to clomipramine inhibition. In another approach, two glioblastoma cell lines that contain either m.14798T or m.14798C were used to examine the effects of clomipramine treatment on glioblastoma cell viability. Clomipramine-addition markedly inhibited the growth of glioblastoma cells that carry the variant m.14798C compared with the wild-type m.14798T at 24 hours. This may be due to the significant induction of mitochondrial-specific reactive oxygen species by clomipramine, which was only observed in the m.14798C containing glioblastoma cells. Here we provide evidence that a single mtDNA variation can have an effect on mitochondrial targeted drug sensitivity. m.14798T>C is of particular interest as it is germ-line, raising the possibility that glioblastoma patients that inherit this variation will respond better to clomipramine-treatment. These results also suggest that looking in more detail at the mtDNA background of patients could aid the development of personalised glioblastoma therapies.
A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation
Authors: Marina Konopleva, Zeng Zhihong, Rui-Yu Wang, Peter F. Thall, Gloria McCormick, Hongbo Lu, Julianne J Chen, Elizabeth J. Shpall, Stefan O. Ciurea, Partow Kebriaei, Amin M Alousi, Uday Popat, Paolo Anderlini, Yago Nieto, Simrit Parmar, Becky McMullin, Gabriela Rondon, Wendy D. Schober, Alison Gulbis, Rita Cool, E. Lin, Michael Andreeff, Richard Champlin
Journal: Blood (2010)
Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL
Authors: Jae H. Park, Isabelle Rivière, Xiuyan Wang, Jolanta Stefanski, Qing He, Clare Taylor, Malgorzata Olszewska, Teresa Wasielewska, Shirley Bartido, Marco L Davila, Yvette Bernal, Nicole Lamanna, Ariela Noy, Michel Sadelain, Renier J Brentjens
Journal: Blood (2012)
Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition
Authors: Alex Kentsis, Takaomi Sanda, Casie Reed, Scott J. Rodig, Eleni Tholouli, Vu Ngo, Jeffery Lorne Kutok, Suzanne E. Dahlberg, Lisa A Moreau, George Vande Woude, James Christensen, Richard Byers, Andrew L. Kung, Louis M. Staudt, Thomas Look
Journal: Blood (2011)
Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.
Authors: Richard Champlin, Daniel Booser, Gabriela Rondon, Patricia Williams, Richard Wendt, Gabriel Hortobagyi, Naoto Ueno, Donald Podoloff
Journal: Blood (2004)
Germline IgVH, del(17p13.1) and del(11q22.3) Predict Duration of Response in Patients Affected by Chronic Lymphocytic Leukaemia Treated with Oral Fludarabine and Cyclophosphamide as First-Line Therapy.
Authors: Luca Laurenti, Dimitar Efremov, Michela Tarnani, Laura de Padua, Nicola Piccirillo, Patrizia Chiusolo, Federica Sora’, Simona Sica, Gina Zini, Mariagrazia Garzia, Giuseppe Leone
Journal: Blood (2007)
Surgery Treatment and Pathological Results of Patients of Malignant Hematological Disorders Complicated with Lung Diseases.
Authors: Xiaowen Tang, Haoyue Huang, Shenghua Zhan, Xingwei Sun, Xiaolan Shi, Aining Sun, Zhenya Shen, Suya Kang, Wu Depei, Zhengming Jin, Huiying Qiu, Miao Miao, Chengcheng Fu, Yue Han, Suning Chen, Shengli Xue, Xiao Ma
Journal: Blood (2009)
Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients
Authors: C. Villa, M. Meregaglia, C. Rognogni, P. Pistillo, E. Orlandi, A. Iacovelli, R. Granata, S. Alfieri, C. Bergamini, C. Resteghini, L. Locati, P. Bossi, M. Guzzo, L. Licitra, F. Favales
Journal: Annals of Oncology (2016)
Note on the Occurrence of Hepatomas in Rats Following the Ingestion of 1,2-Benzanthracene
Authors: Florence R. White, Allen B. Eschenbrenner
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Note on the Occurrence of Hepatomas in Rats Following the Ingestion of 1,2-Benzanthracene Get access Florence R. White, Florence R. White Search for other works by this author on: Oxford Academic PubMed Google Scholar Allen B. Eschenbrenner Allen B. Eschenbrenner Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 19–21, https://doi.org/10.1093/jnci/6.1.19 Published: 01 August 1945
RTHP-29. COMPLIANCE AND DURATION OF TREATMENT WITH TUMOR TREATING FIELDS (TTFIELDs) IN ADJUVANT TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) IMPROVES PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS)
Authors: Vaibhav Kumar, David Harris
Journal: Neuro-Oncology (2016)

A recent randomized controlled trial combining TTFields with temozolomide for the adjuvant treatment of GBMs significantly increased both patient OS and PFS (Stupp et al, JAMA 2015). The primary objectives of this study are to determine whether device compliance and duration of treatment led to improved PFS and OS. A secondary objective is to determine what factors contributed to increased compliance and duration of treatment. Temozolomide was given at 150-200mg/m2, five days out of every 28 days with TTFields applied via four plastic arrays containing electrodes > = 18 hour/day. Demographics from the ten patients enrolled into the trial at our institution were collected and analyzed. Our institution accrued 17 patients into the trial, 10 of whom were randomized to receive TTFields. Median PFS and OS in the patients receiving the device were 12 (IQR: 9-36) and 25 (IQR: 16-47) mos, respectively, compared to the estimated control patients in the trial of 4.0 (95% CI: 3.3-5.2) and 15.6 (95% CI: 16.7-25.0) mos, respectively. The correlation coefficient for duration of treatment and PFS was 0.42 (p=0.27) and OS was 0.37(p=0.33). Subject-level median device compliance had a correlation coefficient with PFS and OS of 0.23 (p = 0.55) and 0.38 (p = 0.31), respectively. Extent of resection [GTR (>95%) vs. NTR, STR, and Biopsy] was associated with improved duration of treatment, 21 vs 8 months (p = 0.30), increased PFS, 40.00 vs 9.00 months (p = 0.048) and OS, 50.00 vs 16.00 months (p = 0.048). Increased compliance positively correlated with improved OS; duration of treatment positively correlated with PFS and OS. Extent of resection improved duration of treatment, PFS and OS, suggesting that patients with aggressive resections are the best candidates for treatment with TTFields. These results will need to be verified in a larger data set.
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts
Authors: P.S. Boonstra, T.M. Braun, J.M.G. Taylor, K.M. Kidwell, E.L. Bellile, S. Daignault, L. Zhao, K.A. Griffith, T.S. Lawrence, G.P. Kalemkerian, M.J. Schipper
Journal: Annals of Oncology (2017)
P17.02 Diagnostic delay and treatment options of Primary Central Nervous System Lymphoma in the last decade: preliminary results of first 50 patients from two Catalan institutions
Authors: R. Velasco, S. Mercadal, N. Vidal, A. López-Guillermo, J. Bruna, F. Graus
Journal: Neuro-Oncology (2016)

AbstractBackground:Primary central nervous system lymphoma (PCNSL) is a challenging disease frequently misdiagnosed and associated with a considerable diagnostic delay. The aim of this study was to ascertain the diagnostic management and frequency of untreated PCNSL in two academic hospitals (Institut Catala d´Oncologia, L´Hospitalet and Hospital Clinic, Barcelona).Methods:We reviewed the clinical records of all non-immunosuppressed PCNSL patients diagnosed between2005 and2014.Results:We identified 50 patients, 34 (68%) were men. Median age was 61.5 [range 30–79] years old and 45 (90%) were of B-cell origin. Most frequent symptoms at clinical presentation were: focal deficit (56%), cognitive impairment (17%), vertigo (18%), psychiatric (10%), visual (10%) and seizures (8%). MRI was performed in the almost all of patients (98%) at a median of 18 [range 1–104] days after the first symptom onset. Multiple and bilateral localization at presentation was observed in 23 (46%) and 19 (38%) patients, respectively. Typical homogeneous contrast enhancement was present in 30 (60 %) patients, being atypical (ring or non-homogeneous) in 14 (28%). In 4 (8%) patients the lesions did not enhance with gadolinium. Median time to pathological diagnosis from clinical onset was 49 days [95% confidence interval (CI), 36.90–61.09 days] with no differences between patients who were treated or not with steroids (58 vs 42.5 days, p=0.563). PCNSL was confirmed by surgery in 47 (94%) patients. The other 3 patients were diagnosed by CSF cytology (2) or by necropsy (1). Complementary studies were PET (52%), body-TC (50%), bone-marrow (42%), lumbar puncture (36%), and ophthalmologic examination (18%). Only 39 (78%) patients received specific oncologic treatment. Reasons to withheld treatment included poor performance status and/or old age.Conclusion:Our study indicates that the delay between onset of symptoms and diagnosis is too long and that corticoid administration doesn’t seem to be the main reason for this delay. Nearly one out of 4 patients is not treated after diagnosis. Currently a similar study is underway in 20 additional institutions from Spain to confirm these results.
Endoplasmic Reticulum Stress Is a Target for Therapy in Paroxysmal Nocturnal Hemoglobinuria.
Authors: Regis Peffault de Latour, Valeria Visconte, Keyvan Keyvanfar, Olga Nunez, Marie Desierto, Jichun Chen, Adrian Wiestner, Neal S Young
Journal: Blood (2009)
CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis
Authors: Yu-Tzu Tai, Yosef Landesman, Chirag Acharya, Mike Y Zhong, Yolanda Calle, Michele Cea, Yiguo Hu, Antonia Cagnetta, Daniel Tannenbaum, Michelle Chen, Aditya Munshi, William Senapedis, Jean-Richard Saint-Martin, Trinayan Kashyap, Haoqiang Ying, Dilara McCauley, Sharon Shacham, Michael Kauffman, Yumei Gu, Lizi Wu, Stephen Schey, Andrew L. Kung, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson
Journal: Blood (2012)
Optimized neoantigen selection based on tumor exome data
Authors: C. Kyzirakos, C. Mohr, S. Armeanu-Ebinger, M. Feldhahn, D. Hadaschik, M. Walzer, D. Döcker, M. Menzel, S. Nahnsen, O. Kohlbacher, S. Biskup
Journal: Annals of Oncology (2016)
Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)
Authors: Francois Guilhot, François-Xavier Mahon, Joelle Guilhot, Francoise Rigual-Huguet, Frederic Maloisel, Philippe Rousselot, Martine Gardembas, Selim Corm, Agnes Guerci, Anne Vekhoff, Gabriel Etienne, Laurence Legros, Jean- Jacques Kiladjian, Eric Jourdan, Michele Schoenwald, Marc Berger, Virginie Eclache, Catherine Roche-Lestienne, Franck E Nicolini, Claude Preudhomme
Journal: Blood (2008)
CSIG-19. RECEPTOR TYROSINE KINASE PHOSPHORYLATION IN A MODEL SYSTEM OF GBM
Authors: Amanda Gerber, Matthaeus Ware, Kaitlin Thomas, Michael Blough, Gregory Cairncross
Journal: Neuro-Oncology (2016)

Glioblastoma Multiforme (GBM) is the most common brain tumour in adults, and despite our best treatments is fatal. Multiple receptor tyrosine kinases (RTKs) are amplified in GBM: 45% have elevated expression of Epidermal Growth Factor Receptor (EGFR) and 13% overexpress Platelet Derived Growth Factor Receptor (PDGFR). While the proposed role of RTKs in GBM initiation and maintenance make them attractive therapeutic targets the clinical efficacy of RTK inhibition has been limited: targeting PDGFR has been unsuccessful, and only 10-20% of patients respond incompletely and briefly to EGFR inhibition. Therapeutic advances may be possible if we can understand why these targeted treatments have been ineffective. Using a murine model of PDGF-AA initiated GBM, the role of RTKs in sustaining proliferative signaling was explored. Phospho-RTK arrays, which provide the phosphorylation status of a broad spectrum of RTKs were used to characterize cell lines, and tyrosine kinase inhibitors were used to asses the role of RTKs in sustaining viability. Transformed cell lines retained phosphorylation of PDGFRα in the PDGF-AA independent state. Concurrent phosphorylation of additional receptors was also observed. Five different patterns of phosphorylation were documented: PDGFRα alone and PDGFRα in combination with EGFR, IGFR, AXL-R or HGFR. These patterns of phosphorylation were retained in orthotopic xenografts and remained consistent over time as these cell lines transitioned from the pre-transformed to transformed state. Targeted treatments revealed PDGFRα inhibition in cell lines with co-phosphorylation had minimal effect on cell viability. However, when multiple RTKs are targeted overall receptor phosphorylation and viability decreased. The simultaneous activation of multiple RTKs has been observed in this model, suggesting that multiple RTKs may be involved in sustaining these murine GBMs. If these findings also apply to human GBM, resistance to single RTK inhibitors can be expected and combination therapies needed.
T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development
Authors: Amanda L. Christie, Samuel Y. Ng, Raphael Koch, Alexandra N. Christodoulou, Tiffany DeSouza, Mark A. Murakami, Moony Tseng, Anson Peng, Vadim Molla, Caron A. Jacobson, Brent Shoji, Nicole R. LeBoeuf, Monica Bertagnolli, Philippe Armand, Geraldine S Pinkus, Jesse Boehm, Margaret A. Shipp, David M. Dorfman, Eric D. Jacobsen, David C. Fisher, Elizabeth A. Morgan, Jon C. Aster, David M. Weinstock
Journal: Blood (2016)
Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.
Authors: Masamitsu Yanada, Tomoki Naoe, Hiroatsu Iida, Yoshiko Atsuta, Kazuhito Yamamoto, Junji Tanaka, Satoshi Takahashi
Journal: Blood (2005)
A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.
Authors: Ana-Iris Schiefer, Michael Melcher, Zsuzsanna Bago-Horvath, Sandra Eder, Cathrin Skrabs, Alexander Hauswirth, Berthold Streubel, Christine Mannhalter, Dagmar Stoiber, Veronika Sexl, Leonhard Müllauer, Ulrich Jaeger, Edit Anna Porpaczy
Journal: Blood (2012)